I Holland Holds a Seminar to Offer Answers to Common Tablet Tooling Problems
In their quest to educate punch and die users on solving tablet tooling issues, I Holland will hold a seminar 5–6 November to address the most common problems that affect most tablet manufacturers.
Having researched the issues related to tablet compression, and devised a structured programme to combat the problems, I Holland will share their findings in a seminar designed to give an in-depth technical view on troubleshooting from a tablet manufacturers perspective.
Clare Taylor, I Hollands Marketing Manager said: The Troubleshooting in Tablet Tooling seminar has run on several occasions and has proved to be extremely popular. We now hold the event three times per year. We want to continue to educate the industry on how they can solve common tablet production problems with better foresight and understanding of the potential causes, whilst offering practical solutions which will result in saving not just time, but also money.
The seminar is designed to highlight the most prolific problems in tablet manufacture and offer answers to each issue. It also demonstrates how tool life can be maximised by adopting I Hollands recommended professional maintenance and storage programme, the PharmaCare 7-Step Process.
The seminar will combine a practical element and demonstrate how this process works. There will also be a tour of the I Holland plant, where delegates can see punch manufacture from design through to despatch of the final product. It will also give us the opportunity to discuss individual cases with those that attend and gain informative feedback on how I Holland can further assist in problem solving tooling problems.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.